Clinical Trials Browser

Phase 2 × Urothelial Bladder Carcinoma × sacituzumab govitecan × Clear all

NCT06133517 2026-03-16

PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer

Phase 2 Active not recruiting

Urothelial Bladder Carcinoma